IPP Bureau
USFDA inspects Piramal Pharma Lexington facility
By IPP Bureau - January 12, 2023
The company is preparing a detailed response to the observations, which will be submitted to the USFDA within the stipulated timelines.
HLL pays Rs. 122.47 crore as dividend to Government of India for FY 21-22
By IPP Bureau - January 12, 2023
The company has played an important role in the procurement and distribution of emergency medical supplies supporting the Union Health Ministry for Covid–19 pandemic management
Sun Pharma launches Palbociclib, a novel targeted therapy for advanced breast cancer
By IPP Bureau - January 12, 2023
Palbociclib has a unique mechanism of action which helps in delaying disease progression when co-administered with hormonal therapies
Genome sequencing solutions will help to bring precision in lung cancer therapy, says GlobalData
By IPP Bureau - January 12, 2023
APAC region contributed around 50% of the in-vitro diagnostics market in 2022
Apollo Genomics Institutes launched at Apollo Hospitals Navi Mumbai
By IPP Bureau - January 12, 2023
Launch of Apollo Genomics Institutes would provide genetic counselling, tests, treatment and care for genetic disorders
Merck completes tender offer to acquire Imago BioSciences
By IPP Bureau - January 12, 2023
Merck intends to complete today the acquisition of Imago through a merger of Merck’s wholly owned subsidiary with and into Imago
Moderna to acquire Oriciro Genomics
By IPP Bureau - January 11, 2023
OriCiro's synthetic biology and enzyme technologies will support Moderna's expanding portfolio of therapeutics and vaccines
Moderna and CytomX partner for mRNA-based conditnionally activated therapeutics
By IPP Bureau - January 11, 2023
Collaboration to generate and develop therapeutics for oncology and non-oncology conditions
Merck named one of America’s Most JUST Companies by JUST Capital and CNBC
By IPP Bureau - January 11, 2023
The JUST 100 is the only ranking that recognizes companies doing right by all their stakeholders as defined by the American public.
Lupin and Exeltis announce reimbursement approval of NaMuscla in Spain
By IPP Bureau - January 10, 2023
NDM disorders are a group of rare, inherited neuromuscular disorders with an estimated prevalence of 1 case per 100,000 inhabitants in Spain, and are characterized by the inability to relax muscles following voluntary contraction (myotonia)
Sirio Pharma successfully completes acquisition of Best Formulations
By IPP Bureau - January 10, 2023
With more than 35 years of experience, Best Formulations is the largest manufacturer of plant-based softgels in the United States, with newly expanded capabilities for nutritional gummies and personal care
NHA introduces new system to measure hospitals performance empaneled under AB PM-JAY Scheme
By IPP Bureau - January 10, 2023
The objective of this system is to shift the focus of measuring performance of hospitals from volume of services provided to value of healthcare services
Vidita Vaidya awarded Infosys Prize 2022 in Life Sciences
By IPP Bureau - January 10, 2023
In a time when conversations around mental health have become ever more urgent Vaidya’s work is extremely contextual
Moderna announces advances across mRNA pipeline
By IPP Bureau - January 10, 2023
Moderna and Merck announced mRNA-4157/V940, in combination with KEYTRUDA, demonstrated a 44% reduction in the risk of disease recurrence or death in melanoma patients
GenNext Technologies appoints Dr. John Grant to its Board of Directors
By IPP Bureau - January 10, 2023
Dr. Grant brings to the table significant BOD governance, global business development, and corporate development expertise
